IMMUNITYBIO
NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. They discover and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks. The company was incorporated in 2014 and is based in Culver City, California.
IMMUNITYBIO
Industry:
Health Care Health Diagnostics Therapeutics
Founded:
2014-01-01
Address:
Culver City, California, United States
Country:
United States
Website Url:
http://www.immunitybio.com
Total Employee:
101+
Status:
Active
Contact:
(310) 883-1300
Total Funding:
182.66 M USD
Technology used in webpage:
SPF Google Analytics Wordpress Plugins Microsoft Azure DNS US Privacy User Signal Mechanism GoDaddy DNS Cloudflare Person Schema Gravatar Profiles Cloudflare Network Error Logging
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Helomics
Helomics provides comprehensive tumor profiling utilizing proprietary tissue-based live cell and fixed cell products and services.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-12-21 | NantKwest | NantKwest acquired by ImmunityBio | N/A |
| 2017-06-27 | Altor BioScience | Altor BioScience acquired by ImmunityBio | 290 M USD |
| 2015-06-23 | VivaBioCell | VivaBioCell acquired by ImmunityBio | N/A |
Investors List
Patrick Soon-Shiong
Patrick Soon-Shiong investment in Private Equity Round - ImmunityBio
Key Employee Changes
Official Site Inspections
http://www.immunitybio.com Semrush global rank: 1.8 M Semrush visits lastest month: 12.68 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ImmunityBio"
Immunotherapy by ImmunityBio - Cancer Vaccine Research
Nov 19, 2024 · ImmunityBio’s platforms address the entire immune system, harnessing the power of both innate and adaptive functions of the immune system by activation of ‘first responder’ …See details»
ImmunityBio is on a Mission
ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious disease. Since then we have progressed into a clinical …See details»
Immunotherapy and Cell Therapy Platforms
ImmunityBio’s next-generation vaccine platform, the human adenovirus 5 (hAd5) vector with advanced modifications, offers an opportunity for a broader immune response that includes vigorous T-cell mediated responses.See details»
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in …
ImmunityBio management will discuss FDA approval of ANKTIVA in combination with BCG for the treatment of BCG-unresponsive NMIBC via a conference call and webcast on Fri., April 26, …See details»
ImmunityBio - Crunchbase Company Profile & Funding
ImmunityBio is a late-stage immunotherapy startup that is developing treatments to drive immunogenic pathways in the fight against cancer. ImmunityBio reported its first quarter 2024 earnings, where revenues exceeded expectations, …See details»
ImmunityBio, Inc. - LinkedIn
Outsmart Your Disease™ | ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system,...See details»
ImmunityBio Investor Presentation
ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder …See details»
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of …
Nov 19, 2024 · More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 10-K filed with the …See details»
ImmunityBio Company Profile - Office Locations, Competitors
Oct 29, 2024 · ImmunityBio (formerly known as NantKwest) is a clinical-stage immunotherapy company focused on harnessing the power of the immune system using natural killer (NK) …See details»
Fighting a war on two fronts: ImmunityBio targets …
ImmunityBio is applying its second-generation human adenovirus 5 vaccine platform, used as part of its orchestrated multi-modal treatment approach to advanced cancer, to prevent...See details»
ImmunityBio Announces Completion of $470 Million Post-Merger …
Dec 20, 2021 · CULVER CITY, Calif., December 20, 2021- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has successfully raised an aggregate $470 million of …See details»
ImmunityBio - Overview, News & Similar companies - ZoomInfo
ImmunityBio contact info: Phone number: (844) 696-5235 Website: immunitybio.com What does ImmunityBio do? ImmunityBio is a leading late-clinical-stage immunotherapy company …See details»
ImmunityBio and nCartes Enter Collaboration Agreement on …
Nov 21, 2024 · ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform provider, announced a …See details»
First-in-class IL-15 receptor agonist nabs FDA approval for
Apr 26, 2024 · The US FDA has approved ImmunityBio’s nogapendekin alfa inbakicept (Anktiva) in combination with the Bacillus Calmette–Guérin (BCG) vaccine for BCG-unresponsive non …See details»
ImmunityBio and NantKwest to Merge, Creating a Leading …
Dec 21, 2020 · CULVER CITY & EL SEGUNDO, Calif., December 21, 2020 — ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, …See details»
ImmunityBio COVID-19 vaccine - Wikipedia
The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a non replicating viral vector [1] COVID-19 vaccine developed by the United States-based pharmaceutical company …See details»
ImmunityBio Announces Completion of $470 Million Post-merger …
Dec 20, 2021 · CULVER CITY, Calif.-- (BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has successfully raised an aggregate $470 million of …See details»
ImmunityBio and nCartes Enter Collaboration Agreement on
Nov 21, 2024 · --ImmunityBio, Inc., a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform provider, announced a collaboration …See details»
ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of ...
Apr 23, 2024 · FDA approved ImmunityBio, Inc.'s ANKTIVA for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without …See details»
ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix …
Nov 18, 2021 · ImmunityBio is a leading late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and …See details»